The most common side effects include gastrointestinal disorders, such as [[dyspepsia]], [[decreased appetite]], [[nausea]], [[vomiting]], [[abdominal pain]], [[diarrhea]].<ref name="pmid24742660">{{cite journal |vauthors=Nauck M, Weinstock RS, Umpierrez GE, Guerci B, Skrivanek Z, Milicevic Z |title=Efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5) |journal=Diabetes Care |volume=37 |issue=8 |pages=2149–58 |date=August 2014  |pmid=24742660 |doi=10.2337/dc13-2761 |url=http://care.diabetesjournals.org/content/37/8/2149.full |accessdate=2015-03-01 |pmc=4113177}}</ref> Some patients may experience serious adverse reactions: [[acute pancreatitis]] (symptoms include persistent severe abdominal pain, sometimes radiating to the back and accompanied by vomiting), [[hypoglycemia]], [[renal impairment]] (which may sometimes require hemodialysis). The risk of hypoglycemia is increased if the drug is used in combination with [[sulfonylureas]] or [[insulin]].<ref name="pmid24918645">{{cite journal |author=Amblee A |title=Dulaglutide for the treatment of type 2 diabetes |journal=Drugs Today |volume=50 |issue=4 |pages=277–89 |date=April 2014  |pmid=24918645 |doi=10.1358/dot.2014.50.4.2132740 |url=}}</ref><ref name="pmid24485345">{{cite journal |vauthors=Monami M, Dicembrini I, Nardini C, Fiordelli I, Mannucci E |title=Glucagon-like peptide-1 receptor agonists and pancreatitis: a meta-analysis of randomized clinical trials |journal=Diabetes Res. Clin. Pract. |volume=103 |issue=2 |pages=269–75 |date=February 2014  |pmid=24485345 |doi=10.1016/j.diabres.2014.01.010 |url=}}</ref>

 

